About Rivermark
Rivermark is a company based in Milwaukee (United States) founded in 2021 by Andy Doraiswamy. Rivermark has raised $34.16 million across 2 funding rounds from investors including American Century Investments, Venture Investors and Time BioVentures. Rivermark offers products and services including FloStent. Rivermark operates in a competitive market with competitors including Neotract, Zenflow, Urotronic, Butterfly Medical and ProVerum Medical, among others.
- Headquarter Milwaukee, United States
- Founders Andy Doraiswamy
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Rivermark Medical, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$34.16 M (USD)
in 2 rounds
-
Latest Funding Round
$30.04 M (USD), Series C
Sep 27, 2024
-
Investors
American Century Investments
& 5 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Rivermark
Rivermark offers a comprehensive portfolio of products and services, including FloStent.
Device for BPH treatment to restore urinary flow quickly.
Funding Insights of Rivermark
Rivermark has successfully raised a total of $34.16M across 2 strategic funding rounds. The most recent funding activity was a Series C round of $30.04 million completed in September 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Rivermark
Rivermark has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include American Century Investments, Venture Investors and Time BioVentures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Multiple sectors focused seed & early stage VC firm investing in the US, Europe & Asia
|
Locked | Locked | Locked | |
|
Venture capital firm focused on life science and healthcare sectors
|
Locked | Locked | Locked | |
|
Early-stage medical and health technology investments are facilitated.
|
Locked | Locked | Locked |
Investor details for Rivermark
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Rivermark
Investment portfolio details for Rivermark
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Rivermark
Detailed financials for Rivermark
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Rivermark Comparisons
Peer comparison for Rivermark
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Rivermark
Rivermark operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Neotract, Zenflow, Urotronic, Butterfly Medical and ProVerum Medical, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Minimally invasive devices in urology
|
|
| Locked | Locked | Locked |
A device is developed to treat urinary obstruction from BPH.
|
|
| Locked | Locked | Locked |
Urethral stricture treatment devices are developed by Urotronic.
|
|
| Locked | Locked | Locked |
Developer of an implantable device for the treatment of benign prostatic hyperplasia (BPH)
|
|
| Locked | Locked | Locked |
Developer of a minimally-invasive medical device for benign prostatic hyperplasia
|
Detailed competitors of Rivermark
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Rivermark
Complete news archive for Rivermark
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Rivermark
Rivermark was founded in 2021 and raised its 1st funding round 2 years after it was founded.
Rivermark is headquartered in Milwaukee, United States. It is registered at Milwaukee, Wisconsin, United States.
Adam Kadlec is the current CEO of Rivermark.
Rivermark is a funded company, having raised a total of $34.16M across 2 funding rounds to date.
Established in 2021 in Milwaukee, United States, the company operates in the medical device sector. Focus is placed on a minimally invasive solution called FloStent, which utilizes a nitinol stent to keep the prostatic urethra open. Normal urinary function is thereby restored for patients with benign prostatic hyperplasia. Leadership includes co-founder Andy Doraiswamy as chairman and Adam Kadlec as CEO.
Rivermark offers FloStent.
Rivermark has 6 investors. Key investors include American Century Investments, Venture Investors, Time BioVentures, View Ventures, and Cadence Healthcare Ventures.